Imagine a world where diagnosing brain diseases is faster, more accurate, and less reliant on subjective human interpretation. That future is closer than you think! Philips and Cortechs.ai are joining forces to revolutionize neurological care, promising a new era of precision diagnostics. But here's where it gets controversial: will AI ever truly replace the nuanced judgment of experienced doctors?
Amsterdam, Netherlands – November 19, 2025 – Royal Philips, a global leader in health technology, is doubling down on its commitment to brain health by extending its partnership with Cortechs.ai, a pioneering force in the world of quantitative neuroimaging solutions. This isn't just a minor upgrade; it's a strategic alliance designed to integrate Cortechs.ai's advanced, AI-powered neuroimaging analytics directly into Philips' cutting-edge MR (Magnetic Resonance) systems. The goal? To empower clinicians with insights that are not only faster but also more objective and consistently reproducible when assessing brain health. Think of it as giving doctors a super-powered magnifying glass that reveals subtle changes in the brain that might otherwise go unnoticed.
This collaboration significantly strengthens Philips’ position as a leader in precision neuro diagnostics. By combining Philips’ next-generation MR technologies with Cortechs.ai’s AI-driven quantitative neuroimaging post-processing software, they aim to fundamentally transform how neurological diseases are detected, monitored, and ultimately, managed. This means earlier diagnoses, more effective treatment plans, and ultimately, better outcomes for patients.
Combining Expertise for a Smarter Approach to Brain Imaging
Consider this: a staggering 25% of all MR procedures are dedicated to brain scans. And this number is only expected to rise, putting immense pressure on radiology departments already grappling with increasing staff shortages. At the same time, the number of individuals affected by neurological conditions such as Alzheimer’s disease, multiple sclerosis (MS), and brain tumors continues its relentless climb worldwide. The current methods of interpreting MR images for neurodegenerative diseases or neuro-oncology cases often rely heavily on visual assessment. This introduces a degree of variability, as different doctors might interpret the same image slightly differently. It also demands significant expertise and time, further burdening an already overloaded healthcare system. And this is the part most people miss: subtle changes, indicative of early-stage disease, can easily be overlooked with the naked eye.
The extended partnership between Philips and Cortechs.ai is laser-focused on delivering more standardized and data-driven imaging. Imagine having access to objective, numerical data alongside the traditional images. By seamlessly integrating quantitative analysis tools – such as brain volumetrics (measuring the size of different brain regions), lesion quantification (counting and measuring lesions), and tumor tracking – directly into the Philips MR imaging workflow, clinicians gain precisely that. This empowers them to make diagnoses that are not only faster but also more consistent and, most importantly, more confident.
Empowering Clinicians with Precision and Speed
The integration of Cortechs.ai’s NeuroQuant® solutions for Alzheimer’s, MS, and brain tumors within Philips’ Smart Reading environment is a game-changer. Smart Reading, a cloud-based AI platform, seamlessly combines imaging, reading, and reporting directly on the MR systems. This integration marks a major leap forward in the pursuit of precision neuroimaging.
Here’s how it works: clinicians can automatically receive AI-generated quantitative reports within their standard MR workflow, either directly on the MR system or through their PACS (Picture Archiving and Communication System). This happens without requiring any additional steps from technologists. This
